EcoDrugPlus

Phosphodiesterase 9a

Ensembl ID : ENSACLG00000006122
Gene Symbol: PDE9A
1 Cross references
192 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSACLG00000026675
Gene Symbol: PIK3R1
3 Cross references
203 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSACLG00000023014
Gene Symbol: PIK3R2
1 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSACLG00000022144
Gene Symbol: PIK3R3
3 Cross references
188 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSACLG00000006089
Gene Symbol: PIK3R5
3 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSACLG00000007541
Gene Symbol: PIK3R2
1 Cross references
190 Possible Orthologues:

Phospholipase A2, Group Vii (Platelet-Activating Factor Acetylhydrolase, Plasma)

Ensembl ID : ENSACLG00000007662
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:

Phospholipase A2-Like

Ensembl ID : ENSACLG00000005439
Gene Symbol: LOC113019998
3 Cross references
233 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSACLG00000024571
Gene Symbol: GART
3 Cross references
214 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSACLG00000010734
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Plasminogen-Like

Ensembl ID : ENSACLG00000001255
Gene Symbol: LOC113006847
2 Cross references
223 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSACLG00000015266
Gene Symbol: PTAFR
1 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).